Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (NASDAQ:TWST), filed a Form 4 on August 12, 2026, disclosing the exercise of stock options and the sale of 113,318 shares of common stock on August 10, 2026, pursuant to a previously established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Leproust acquired 113,318 shares of common stock via an "M" (exercise of in-the-money or at-the-money derivative) transaction at an exercise price of $26.66 per share.
  • Shares sold: 113,318 shares were disposed of at a weighted average price of $125.1615 per share, with individual sale prices ranging from $125.00 to $125.51 per share.
  • Post-transaction ownership: Following the reported transactions, Leproust directly beneficially owned 818,938 shares of common stock.
  • 10b5-1 plan: According to the filing, the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Leproust on May 27, 2025.
  • Remaining options: Leproust continues to hold employee stock options covering shares at exercise prices of $23.33, $67.85, $8.82, and $26.66, with 153,221 shares remaining under the $26.66 option following the reported exercise.

Leproust Option Exercise and Share Sale Details at Twist Bioscience

According to the filing, Emily M. Leproust, who serves as both Chief Executive Officer and a Director of Twist Bioscience Corp, executed two linked transactions on August 10, 2026. She first exercised employee stock options to acquire 113,318 shares of common stock at an exercise price of $26.66 per share, bringing her directly held position to 932,256 shares. She then disposed of all 113,318 of those shares at a weighted average sale price of $125.1615 per share. The filing notes that shares were sold at prices ranging from $125.00 to $125.51 per share, and that full detail on the number of shares sold at each price is available upon request to the SEC staff, the issuer, or a security holder.

The filing states that both transactions were carried out under a Rule 10b5-1 trading plan that Leproust previously adopted on May 27, 2025. The exercised option had an exercise price of $26.66 and, according to the filing, 20% of the underlying shares vested and became exercisable on October 31, 2019, with 1/60th vesting on each monthly anniversary thereafter, subject to continuous service. After the exercise, 153,221 shares remain under that option with an expiration date of November 18, 2028.

In addition to the options associated with the reported exercise, the filing discloses that Leproust holds other employee stock options: 131,290 shares at $23.33 (expiring October 23, 2029), 64,950 shares at $67.85 (expiring August 31, 2030), and 75,439 shares at $8.82 (expiring September 28, 2027), all held directly. A separate option at $5.95 is listed with zero shares remaining. The filing was signed by Kendra Fox as Attorney-in-Fact for Emily M. Leproust on August 12, 2026.

What Was Disclosed

The filing reports that Twist Bioscience CEO Emily M. Leproust exercised options for and then sold 113,318 shares of common stock on August 10, 2026, under a pre-established 10b5-1 plan, leaving her with direct beneficial ownership of 818,938 shares.